Penicillamine and Glomerulonephritis rapidly progressive - a phase IV clinical study of FDA data

Summary:

Glomerulonephritis rapidly progressive is reported as a side effect among people who take Penicillamine (penicillamine), especially for people who are female, 10-19 old, also take Methotrexate, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Glomerulonephritis rapidly progressive when taking Penicillamine. It is created by eHealthMe based on reports of 1,329 people who have side effects when taking Penicillamine from the FDA, and is updated regularly.

What is Penicillamine?

Penicillamine has active ingredients of penicillamine. eHealthMe is studying from 1,329 Penicillamine users. Check the latest studies of Penicillamine.

What is Glomerulonephritis rapidly progressive?

Glomerulonephritis rapidly progressive (a syndrome of the kidney that is characterized by a rapid loss of renal function) is found to be associated with 88 drugs and 203 conditions by eHealthMe. Check the latest studies of Glomerulonephritis rapidly progressive.

On Jul, 14, 2026

1,329 people reported to have side effects when taking Penicillamine.
Among them, 11 people (0.83%) have Glomerulonephritis rapidly progressive.

Could Penicillamine cause Glomerulonephritis rapidly progressive?

Among these 11 people:

What is the gender of people who have Glomerulonephritis rapidly progressive when taking Penicillamine? *

female: 80 %
male: 20 %

What is the age of people who have Glomerulonephritis rapidly progressive when taking Penicillamine? *

What are other drugs people take besides Penicillamine? *

Sulfasalazine: 1 person, 9.09%
Remicade: 1 person, 9.09%
Methotrexate: 1 person, 9.09%

What are other side effects people have besides Glomerulonephritis rapidly progressive? *

Acute Kidney Failure: 5 people, 45.45%
Pulmonary Alveolar Haemorrhage (acute bleeding): 4 people, 36.36%
Pleural Effusion (water on the lungs): 2 people, 18.18%
Glomerulonephritis Membranous (nephritis with inflammation of the capillary loops in the renal glomeruli): 2 people, 18.18%
Hair Loss: 2 people, 18.18%
Microcytic Anaemia (a generic term for any type of anaemia characterized by small red blood cells): 2 people, 18.18%
Weight Decreased: 2 people, 18.18%
Renal Impairment (severely reduced kidney function): 2 people, 18.18%
Pneumonia: 1 person, 9.09%
Pericardial Effusion (fluid around the heart): 1 person, 9.09%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 18.18%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 9.09%
Immunodeficiency Disorders: 1 person, 9.09%
Autoimmune Disorder (a condition in which the immune system attacks the body's normal substances and tissue): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Penicillamine and have Glomerulonephritis rapidly progressive?

- Check whether Glomerulonephritis rapidly progressive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Penicillamine:

Penicillamine (1,329 reports)

Glomerulonephritis rapidly progressive treatments and more:

Glomerulonephritis rapidly progressive (1,483 reports)

How severe was Glomerulonephritis rapidly progressive and when was it recovered:

Glomerulonephritis rapidly progressive in Penicillamine

Expand to all the drugs that have ingredients of penicillamine:

Glomerulonephritis rapidly progressive and drugs with ingredients of penicillamine

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Penicillamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glomerulonephritis rapidly progressive:

Glomerulonephritis rapidly progressive (88 drugs)

Browse all the conditions that are associated with Glomerulonephritis rapidly progressive:

Glomerulonephritis rapidly progressive (203 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on penicillamine (the active ingredients of Penicillamine) and Penicillamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.